Previous 10 | Next 10 |
2024-05-06 17:35:20 ET More on STAAR Surgical STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript ...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 2...
2024-04-05 10:13:16 ET STAAR Surgical (NASDAQ: STAA) received an upgrade from William Blair on Friday. The stock has been moved from Market Perform to Outperform status. STAAR Surgical shares rose by over 13% on Thursday after the company issued strong preliminary first-quar...
2024-04-05 09:00:19 ET Summary STAAR Surgical stock surged by 16.5% after reporting higher than expected preliminary sales for Q1 of fiscal year 2024. The company's ICL offering in the US and other regions showed positive growth, but profitability and cash flows have been declinin...
2024-04-05 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-04 17:00:03 ET Margaret Kaczor from William Blair issued a price target of $45.03 for STAA on 2024-04-04 15:25:00. The adjusted price target was set to $45.03. At the time of the announcement, STAA was trading at $45.54. The overall price target consensus is at $...
2024-04-04 07:26:12 ET More on STAAR Surgical STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade STAAR Surgical collaborates with SharpeVision in the U.S. Seeking Alpha’s Quant Rating on STAAR Surgical Read the full article on ...
Total Net Sales in Excess of $77 Million Including Record Quarterly U.S. ICL Sales of $5 Million STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism...
Scientific content at ASCRS related to EVO ICL ™ doubles with 44 posters and presentations STAAR is leading a comprehensive clinical education program including a lunch symposium, multiple in-booth and offsite events, as well as online through the launch of STAAR University ...
2024-03-28 12:39:10 ET Read the full article on Seeking Alpha For further details see: NXST, GNTX, and COKE among the best mid-cap technical ideas - Roth MKM
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA STAAR Surgical Company (NASDAQ: K), a leading developer, manufactu...